{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T17:08:31Z","timestamp":1789664911931,"version":"4.0.1"},"reference-count":64,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,17]],"date-time":"2021-03-17T00:00:00Z","timestamp":1615939200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007076","name":"Fondazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007076","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP150578"],"award-info":[{"award-number":["RP150578"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP170067"],"award-info":[{"award-number":["RP170067"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP170722"],"award-info":[{"award-number":["RP170722"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gastrojournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterology"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1053\/j.gastro.2021.03.022","type":"journal-article","created":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T17:32:03Z","timestamp":1616175123000},"page":"196-210","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Sequential Administration of XPO1 and ATR Inhibitors Enhances Therapeutic Response in TP53-mutated Colorectal Cancer"],"prefix":"10.1053","volume":"161","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5000-9084","authenticated-orcid":false,"given":"Akira","family":"Inoue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick S.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalba","family":"Minelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Tomihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahar Salimian","family":"Rizi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johnathon L.","family":"Rose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Kodama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjana","family":"Srinivasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela L.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andy M.","family":"Zuniga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Mullinax","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahil","family":"Seth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph R.","family":"Daniele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Peoples","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Loponte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kadir C.","family":"Akdemir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tin Oo","family":"Khor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ningping","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Roszik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary M.","family":"Sobieski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Brunell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clifford","family":"Stephan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Giuliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela K.","family":"Deem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Shingu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonathan Lissanu","family":"Deribe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G.","family":"Menter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy P.","family":"Heffernan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Viale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher A.","family":"Bristow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Kopetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio F.","family":"Draetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giannicola","family":"Genovese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5182-3320","authenticated-orcid":false,"given":"Alessandro","family":"Carugo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.gastro.2021.03.022_bib1","first-page":"7","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1053\/j.gastro.2021.03.022_bib2","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nature12213","article-title":"Mutational heterogeneity in cancer and the search for new cancer-associated genes","volume":"499","author":"Lawrence","year":"2013","journal-title":"Nature"},{"key":"10.1053\/j.gastro.2021.03.022_bib3","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nature11252","article-title":"Comprehensive molecular characterization of human colon and rectal cancer","volume":"487","author":"Cancer Genome Atlas","year":"2012","journal-title":"Nature"},{"key":"10.1053\/j.gastro.2021.03.022_bib4","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","article-title":"First-line crizotinib versus chemotherapy in ALK-positive lung cancer","volume":"371","author":"Solomon","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2021.03.022_bib5","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2021.03.022_bib6","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nm.4333","article-title":"Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients","volume":"23","author":"Zehir","year":"2017","journal-title":"Nat Med"},{"key":"10.1053\/j.gastro.2021.03.022_bib7","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1158\/2159-8290.CD-16-1154","article-title":"Personalized in\u00a0vitro and in\u00a0vivo cancer models to guide precision medicine","volume":"7","author":"Pauli","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1053\/j.gastro.2021.03.022_bib8","doi-asserted-by":"crossref","first-page":"4032","DOI":"10.1200\/JCO.2015.63.2497","article-title":"Phase II pilot study of vemurafenib in patients with metastatic BRAF-mutated colorectal cancer","volume":"33","author":"Kopetz","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1053\/j.gastro.2021.03.022_bib9","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1158\/2159-8290.CD-15-1200","article-title":"In\u00a0vivo genetic screens of patient-derived tumors revealed unexpected frailty of the transformed phenotype","volume":"6","author":"Bossi","year":"2016","journal-title":"Cancer Discov"},{"key":"10.1053\/j.gastro.2021.03.022_bib10","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1158\/2159-8290.CD-13-0907","article-title":"A\u00a0functional cancer genomics screen identifies a druggable synthetic lethal interaction between MSH3 and PRKDC","volume":"4","author":"Dietlein","year":"2014","journal-title":"Cancer Discov"},{"key":"10.1053\/j.gastro.2021.03.022_bib11","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.celrep.2016.05.063","article-title":"In\u00a0vivo functional platform targeting patient-derived xenografts identifies WDR5-Myc association as a critical determinant of pancreatic cancer","volume":"16","author":"Carugo","year":"2016","journal-title":"Cell Rep"},{"key":"10.1053\/j.gastro.2021.03.022_bib12","doi-asserted-by":"crossref","first-page":"E7301","DOI":"10.1073\/pnas.1705441114","article-title":"In\u00a0vivo loss-of-function screens identify KPNB1 as a new druggable oncogene in epithelial ovarian cancer","volume":"114","author":"Kodama","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.gastro.2021.03.022_bib13","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/nrc1274","article-title":"Nuclear transport and cancer: from mechanism to intervention","volume":"4","author":"Kau","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"10.1053\/j.gastro.2021.03.022_bib14","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/nature19771","article-title":"XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer","volume":"538","author":"Kim","year":"2016","journal-title":"Nature"},{"key":"10.1053\/j.gastro.2021.03.022_bib15","doi-asserted-by":"crossref","first-page":"4621","DOI":"10.1182\/blood-2012-05-429506","article-title":"Selective inhibitors of nuclear export show that CRM1\/XPO1 is a target in chronic lymphocytic leukemia","volume":"120","author":"Lapalombella","year":"2012","journal-title":"Blood"},{"key":"10.1053\/j.gastro.2021.03.022_bib16","doi-asserted-by":"crossref","first-page":"5614","DOI":"10.1158\/0008-5472.CAN-17-1323","article-title":"Therapeutic effects of XPO1 inhibition in thymic epithelial tumors","volume":"77","author":"Conforti","year":"2017","journal-title":"Cancer Res"},{"key":"10.1053\/j.gastro.2021.03.022_bib17","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1158\/1078-0432.CCR-16-1580","article-title":"The second-generation exportin-1 inhibitor KPT-8602 demonstrates potent activity against acute lymphoblastic leukemia","volume":"23","author":"Vercruysse","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.gastro.2021.03.022_bib18","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1158\/1078-0432.CCR-16-1333","article-title":"Inhibition of the nuclear export receptor XPO1 as a therapeutic target for platinum-resistant ovarian cancer","volume":"23","author":"Chen","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.gastro.2021.03.022_bib19","doi-asserted-by":"crossref","first-page":"4142","DOI":"10.1200\/JCO.2015.65.3949","article-title":"First-in-class, first-in-human phase I study of selinexor, a selective inhibitor of nuclear export, in patients with advanced solid tumors","volume":"34","author":"Abdul Razak","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1053\/j.gastro.2021.03.022_bib20","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1158\/2159-8290.CD-NB2019-085","article-title":"XPO1 inhibitor approved for multiple myeloma","volume":"9","year":"2019","journal-title":"Cancer Discov"},{"key":"10.1053\/j.gastro.2021.03.022_bib21","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1038\/nrg3317","article-title":"Evolution of the cancer genome","volume":"13","author":"Yates","year":"2012","journal-title":"Nat Rev Genet"},{"key":"10.1053\/j.gastro.2021.03.022_bib22","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1038\/nm.3392","article-title":"Tumor adaptation and resistance to RAF inhibitors","volume":"19","author":"Lito","year":"2013","journal-title":"Nat Med"},{"key":"10.1053\/j.gastro.2021.03.022_bib23","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/1471-2407-5-78","article-title":"Cancer cell adaptation to chemotherapy","volume":"5","author":"Di Nicolantonio","year":"2005","journal-title":"BMC Cancer"},{"key":"10.1053\/j.gastro.2021.03.022_bib24","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/PPO.0b013e318212dd3d","article-title":"Mechanism of cell adaptation: when and how do cancer cells develop chemoresistance?","volume":"17","author":"Fodale","year":"2011","journal-title":"Cancer J"},{"key":"10.1053\/j.gastro.2021.03.022_bib25","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1158\/2159-8290.CD-12-0018","article-title":"Negative feedback and adaptive resistance to the targeted therapy of cancer","volume":"2","author":"Chandarlapaty","year":"2012","journal-title":"Cancer Discov"},{"key":"10.1053\/j.gastro.2021.03.022_bib26","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/nmeth.1351","article-title":"Statistical methods for analysis of high-throughput RNA interference screens","volume":"6","author":"Birmingham","year":"2009","journal-title":"Nat Methods"},{"key":"10.1053\/j.gastro.2021.03.022_bib27","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.canlet.2018.05.029","article-title":"Comprehensive pharmacogenomic profiling of human papillomavirus-positive and -negative squamous cell carcinoma identifies sensitivity to aurora kinase inhibition in KMT2D mutants","volume":"431","author":"Kalu","year":"2018","journal-title":"Cancer Lett"},{"key":"10.1053\/j.gastro.2021.03.022_bib28","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1158\/1535-7163.MCT-16-0721","article-title":"Modeling of patient-derived xenografts in colorectal cancer","volume":"16","author":"Katsiampoura","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"10.1053\/j.gastro.2021.03.022_bib29","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1200\/JCO.2007.14.5482","article-title":"Dose-and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors","volume":"26","author":"Tabernero","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1053\/j.gastro.2021.03.022_bib30","article-title":"Phase II pharmacodynamic trial of palbociclib in patients with KRAS mutant colorectal cancer","volume":"33","author":"O\u2019Hara","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1053\/j.gastro.2021.03.022_bib31","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ejca.2011.11.001","article-title":"A\u00a0phase I, dose-escalation study of the novel polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours","volume":"48","author":"Schoffski","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1053\/j.gastro.2021.03.022_bib32","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nrclinonc.2016.206","article-title":"Proteasome inhibitors in cancer therapy","volume":"14","author":"Manasanch","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1053\/j.gastro.2021.03.022_bib33","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.2174\/1871520614666140919095828","article-title":"Histone deacetylase inhibitors and colorectal cancer: what is new?","volume":"14","author":"Tampakis","year":"2014","journal-title":"Anticancer Agents Med Chem"},{"key":"10.1053\/j.gastro.2021.03.022_bib34","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.bcp.2011.12.016","article-title":"Nuclear export of proteins and drug resistance in cancer","volume":"83","author":"Turner","year":"2012","journal-title":"Biochem Pharmacol"},{"key":"10.1053\/j.gastro.2021.03.022_bib35","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/ng.2653","article-title":"The Genotype-Tissue Expression (GTEx) project","volume":"45","year":"2013","journal-title":"Nat Genet"},{"key":"10.1053\/j.gastro.2021.03.022_bib36","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.cell.2017.07.005","article-title":"Project DRIVE: a compendium of cancer dependencies and synthetic lethal relationships uncovered by large-scale, deep RNAi screening","volume":"170","author":"McDonald","year":"2017","journal-title":"Cell"},{"key":"10.1053\/j.gastro.2021.03.022_bib37","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.gene.2012.02.011","article-title":"Different mutation profiles associated to P53 accumulation in colorectal cancer","volume":"499","author":"Lopez","year":"2012","journal-title":"Gene"},{"key":"10.1053\/j.gastro.2021.03.022_bib38","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1126\/science.2649981","article-title":"Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas","volume":"244","author":"Baker","year":"1989","journal-title":"Science"},{"key":"10.1053\/j.gastro.2021.03.022_bib39","doi-asserted-by":"crossref","first-page":"84","DOI":"10.3748\/wjg.v21.i1.84","article-title":"P53 mutations in colorectal cancer-molecular pathogenesis and pharmacological reactivation","volume":"21","author":"Li","year":"2015","journal-title":"World J Gastroenterol"},{"key":"10.1053\/j.gastro.2021.03.022_bib40","doi-asserted-by":"crossref","first-page":"20475","DOI":"10.1074\/jbc.M213159200","article-title":"The Chk2 tumor suppressor is not required for p53 responses in human cancer cells","volume":"278","author":"Jallepalli","year":"2003","journal-title":"J\u00a0Biol Chem"},{"key":"10.1053\/j.gastro.2021.03.022_bib41","doi-asserted-by":"crossref","first-page":"3964","DOI":"10.1073\/pnas.0813333106","article-title":"A\u00a0panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53","volume":"106","author":"Sur","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.gastro.2021.03.022_bib42","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1002\/ijc.25842","article-title":"Checkpoint kinase inhibitor synergizes with DNA-damaging agents in G1 checkpoint-defective neuroblastoma","volume":"129","author":"Xu","year":"2011","journal-title":"Int J Cancer"},{"key":"10.1053\/j.gastro.2021.03.022_bib43","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20235999","article-title":"Targeting the oncogenic p53 mutants in colorectal cancer and other solid tumors","volume":"20","author":"Li","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1053\/j.gastro.2021.03.022_bib44","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1038\/leu.2016.136","article-title":"Next-generation XPO1 inhibitor shows improved efficacy and in\u00a0vivo tolerability in hematological malignancies","volume":"30","author":"Hing","year":"2016","journal-title":"Leukemia"},{"key":"10.1053\/j.gastro.2021.03.022_bib45","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/leu.2016.145","article-title":"KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells","volume":"31","author":"Etchin","year":"2017","journal-title":"Leukemia"},{"key":"10.1053\/j.gastro.2021.03.022_bib46","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1158\/1538-7445.AM2013-3343","article-title":"Abstract 3343: The pre-clinical in\u00a0vitro and in\u00a0vivo activity of AZD6738: A potent and selective inhibitor of ATR kinase","volume":"73","author":"Guichard","year":"2013","journal-title":"Cancer Res"},{"key":"10.1053\/j.gastro.2021.03.022_bib47","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1038\/nm.3954","article-title":"High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response","volume":"21","author":"Gao","year":"2015","journal-title":"Nat Med"},{"key":"10.1053\/j.gastro.2021.03.022_bib48","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s00535-006-1801-6","article-title":"Colorectal cancer: genetics of development and metastasis","volume":"41","author":"Takayama","year":"2006","journal-title":"J\u00a0Gastroenterol"},{"key":"10.1053\/j.gastro.2021.03.022_bib49","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1038\/sj.onc.1208615","article-title":"The p53 pathway: positive and negative feedback loops","volume":"24","author":"Harris","year":"2005","journal-title":"Oncogene"},{"key":"10.1053\/j.gastro.2021.03.022_bib50","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/35042675","article-title":"Surfing the p53 network","volume":"408","author":"Vogelstein","year":"2000","journal-title":"Nature"},{"key":"10.1053\/j.gastro.2021.03.022_bib51","doi-asserted-by":"crossref","first-page":"3673","DOI":"10.1091\/mbc.e12-01-0045","article-title":"NESdb: a database of NES-containing CRM1 cargoes","volume":"23","author":"Xu","year":"2012","journal-title":"Mol Biol Cell"},{"key":"10.1053\/j.gastro.2021.03.022_bib52","first-page":"229","article-title":"The expression of CRM1 is associated with prognosis in human osteosarcoma","volume":"21","author":"Yao","year":"2009","journal-title":"Oncol Rep"},{"key":"10.1053\/j.gastro.2021.03.022_bib53","doi-asserted-by":"crossref","first-page":"7453","DOI":"10.1038\/sj.onc.1204942","article-title":"Inhibition of Chk1-dependent G2 DNA damage checkpoint radiosensitizes p53 mutant human cells","volume":"20","author":"Koniaras","year":"2001","journal-title":"Oncogene"},{"key":"10.1053\/j.gastro.2021.03.022_bib54","doi-asserted-by":"crossref","first-page":"a012716","DOI":"10.1101\/cshperspect.a012716","article-title":"DNA damage sensing by the ATM and ATR kinases","volume":"5","author":"Marechal","year":"2013","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10.1053\/j.gastro.2021.03.022_bib55","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ccr.2006.11.024","article-title":"p53-deficient cells rely on ATM-and ATR-mediated checkpoint signaling through the p38MAPK\/MK2 pathway for survival after DNA damage","volume":"11","author":"Reinhardt","year":"2007","journal-title":"Cancer Cell"},{"key":"10.1053\/j.gastro.2021.03.022_bib56","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s40265-015-0379-9","article-title":"Palbociclib: first global approval","volume":"75","author":"Dhillon","year":"2015","journal-title":"Drugs"},{"key":"10.1053\/j.gastro.2021.03.022_bib57","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/S1470-2045(17)30422-9","article-title":"Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study","volume":"18","author":"Overman","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.gastro.2021.03.022_bib58","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"10.1053\/j.gastro.2021.03.022_bib59","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 Blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2021.03.022_bib60","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1158\/2159-8290.CD-14-0863","article-title":"The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints","volume":"5","author":"Llosa","year":"2015","journal-title":"Cancer Discov"},{"key":"10.1053\/j.gastro.2021.03.022_bib61","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1053\/j.gastro.2008.01.015","article-title":"Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers","volume":"134","author":"Schwitalle","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2021.03.022_bib62","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/path.2774","article-title":"Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review","volume":"222","author":"Nosho","year":"2010","journal-title":"J\u00a0Pathol"},{"key":"10.1053\/j.gastro.2021.03.022_bib63","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s13045-019-0784-8","article-title":"Prospects for combining immune checkpoint blockade with PARP inhibition","volume":"12","author":"Li","year":"2019","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1053\/j.gastro.2021.03.022_bib64","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/annonc\/mds213","article-title":"Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial","volume":"24","author":"Reck","year":"2013","journal-title":"Ann Oncol"}],"container-title":["Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508521005308?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508521005308?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T19:43:38Z","timestamp":1777405418000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0016508521005308"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":64,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S0016508521005308"],"URL":"https:\/\/doi.org\/10.1053\/j.gastro.2021.03.022","relation":{},"ISSN":["0016-5085"],"issn-type":[{"value":"0016-5085","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sequential Administration of XPO1 and ATR Inhibitors Enhances Therapeutic Response in TP53-mutated Colorectal Cancer","name":"articletitle","label":"Article Title"},{"value":"Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.gastro.2021.03.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by the AGA Institute. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}